Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind Phase 2/3 study of IV amisulpride for prevention of postoperative nausea and vomiting in pediatric patients
2022-002947-23Phase 2Active
- Sponsor
- Acacia Pharma Group Plc
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amisulpride in postoperative nausea and vomiting (PONV) (3 arms), sponsored by Acacia Pharma Group Plc. Primary endpoint: Complete Response during first 24 hours post-surgery. Started Dec 2022; status: active.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2022-002947-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002947-23.